通过准BATF和宫癌中的STAT1/PD-L1途径来增强抗瘤免疫力
Xing Peng1, Yuanyuan Zhu2, Yaqing Han2
1Department of Gynecology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, No.1 Yellow River West Road, Huaiyin District, Huai'an, 223300, China. px0718@njmu.edu.cn.
基本氨酸拉链激活转录因子 (BATF) 促进子宫癌的生长和免疫逃避. 用PD-L1阻塞准BATF可增强抗瘤免疫力,为宫癌提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 宫癌是癌症死亡的主要原因,常常逃避免疫反应.
- 基本氨酸拉链激活转录因子 (BATF) 对T细胞功能至关重要,但其在宫癌中的作用尚不清楚.
研究的目的:
- 研究BATF在宫癌进展和免疫调节中的作用.
- 确定BATF作为一种潜在的治疗点,以增强抗瘤免疫力.
主要方法:
- 在宫癌组织和细胞系中分析了BATF表达.
- 进行了功能测定 (扩散,迁移,入侵) 和体内异种移植研究.
- 通过流细胞计,qRT-PCR和IHC评估免疫细胞群,细胞因子和免疫检查点 (PD-1, TIM-3,LAG-3).
- 研究了BATF通过STAT1途径对PD-L1的调节,并评估了与抗PD-L1.1的联合治疗.
主要成果:
- 在宫癌中,BATF过度表达,与预后不佳相关.
- 随着BATF的淘汰,瘤生长,转移和上皮细胞转移到介质细胞转变 (EMT) 被抑制.
- 缺乏BATF可增强抗瘤免疫力,增加T细胞透和细胞毒性分子,同时减少免疫抑制细胞和免疫检查点.
- BATF通过STAT1调节PD-L1,促进免疫逃避;与BATF敲击和抗PD-L1的联合治疗显示出更高的疗效.
结论:
- 通过STAT1/PD-L1轴,BATF驱动子宫癌的进展和免疫逃避.
- 单独或与PD-L1抑制剂一起向BATF是治疗宫癌的一个有希望的策略.
- 需要进一步的研究来将这些发现转化为临床实践.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
10:04Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway
